NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Gary S. Leiserowitz, Joyce F. Liu, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac‐Lima, Steven W. Remmenga, John O. Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsíros, Mary A. Dwyer, Lisa E. Hang
Abstract
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.